Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
Walid Macaron(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Kelly S. Chien, Nitin B. Jain(Harvard University Press), Jairo Matthews(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(Cellular Therapeutics (United Kingdom)), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Eitan Kugler(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Fadi Haddad(The University of Texas MD Anderson Cancer Center)
Cited by 5
Related Papers
Acute myeloid leukemia: current progress and future directions
|Blood Cancer Journal|2021|750
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
|Journal of Clinical Investigation|2016|499